373OResults of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2018-10, Vol.29 (suppl_8) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | suppl_8 |
| container_start_page | |
| container_title | Annals of oncology |
| container_volume | 29 |
| creator | Peereboom, D Nabors, L B Kumthekar, P Badruddoja, M Fink, K Lieberman, F Phuphanich, S Dunbar, E Walbert, T Schiff, D Tran, D D Ashby, L S Butowski, N Iwamoto, F Lindsay, R Bullington, J Schulder, M Sherman, J Brooks, C Reardon, D |
| description | |
| doi_str_mv | 10.1093/annonc/mdy273.361 |
| format | Article |
| fullrecord | <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdy273_361</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdy273.361</oup_id><sourcerecordid>10.1093/annonc/mdy273.361</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdy273_3613</originalsourceid><addsrcrecordid>eNqV0N9KwzAYBfAgCtY_D-Ddd6nQbkmztfZSZWphIkzvw2ebtZE0KUla6dP4qm7OF_DqwOHAgR8hV4zOGC34HI2xppp39ZTmfMYzdkQitsyK5JYu2DGJaJHyJF_yxSk58_6TUpoVaRGRb57z1430gw4e7Bb6Fr2EsoTgFOp987ZOcspiQDB2lBpU1w3GhlY67CcI6BoZlGmgXCeMbzCNYdW3d7tAU4Mf3KhGZWJQBrD-fflSoQUvK2vqRCsjwclqcE6aAI1W9kOjD7ZDuH66f7m5ICdb1F5e_uU5iR9X7w_PiR160TvVoZsEo2KPIA4I4oAgdgj8n_MfIUlmeA</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>373OResults of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Peereboom, D ; Nabors, L B ; Kumthekar, P ; Badruddoja, M ; Fink, K ; Lieberman, F ; Phuphanich, S ; Dunbar, E ; Walbert, T ; Schiff, D ; Tran, D D ; Ashby, L S ; Butowski, N ; Iwamoto, F ; Lindsay, R ; Bullington, J ; Schulder, M ; Sherman, J ; Brooks, C ; Reardon, D</creator><creatorcontrib>Peereboom, D ; Nabors, L B ; Kumthekar, P ; Badruddoja, M ; Fink, K ; Lieberman, F ; Phuphanich, S ; Dunbar, E ; Walbert, T ; Schiff, D ; Tran, D D ; Ashby, L S ; Butowski, N ; Iwamoto, F ; Lindsay, R ; Bullington, J ; Schulder, M ; Sherman, J ; Brooks, C ; Reardon, D</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy273.361</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2018-10, Vol.29 (suppl_8)</ispartof><rights>The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Peereboom, D</creatorcontrib><creatorcontrib>Nabors, L B</creatorcontrib><creatorcontrib>Kumthekar, P</creatorcontrib><creatorcontrib>Badruddoja, M</creatorcontrib><creatorcontrib>Fink, K</creatorcontrib><creatorcontrib>Lieberman, F</creatorcontrib><creatorcontrib>Phuphanich, S</creatorcontrib><creatorcontrib>Dunbar, E</creatorcontrib><creatorcontrib>Walbert, T</creatorcontrib><creatorcontrib>Schiff, D</creatorcontrib><creatorcontrib>Tran, D D</creatorcontrib><creatorcontrib>Ashby, L S</creatorcontrib><creatorcontrib>Butowski, N</creatorcontrib><creatorcontrib>Iwamoto, F</creatorcontrib><creatorcontrib>Lindsay, R</creatorcontrib><creatorcontrib>Bullington, J</creatorcontrib><creatorcontrib>Schulder, M</creatorcontrib><creatorcontrib>Sherman, J</creatorcontrib><creatorcontrib>Brooks, C</creatorcontrib><creatorcontrib>Reardon, D</creatorcontrib><title>373OResults of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqV0N9KwzAYBfAgCtY_D-Ddd6nQbkmztfZSZWphIkzvw2ebtZE0KUla6dP4qm7OF_DqwOHAgR8hV4zOGC34HI2xppp39ZTmfMYzdkQitsyK5JYu2DGJaJHyJF_yxSk58_6TUpoVaRGRb57z1430gw4e7Bb6Fr2EsoTgFOp987ZOcspiQDB2lBpU1w3GhlY67CcI6BoZlGmgXCeMbzCNYdW3d7tAU4Mf3KhGZWJQBrD-fflSoQUvK2vqRCsjwclqcE6aAI1W9kOjD7ZDuH66f7m5ICdb1F5e_uU5iR9X7w_PiR160TvVoZsEo2KPIA4I4oAgdgj8n_MfIUlmeA</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Peereboom, D</creator><creator>Nabors, L B</creator><creator>Kumthekar, P</creator><creator>Badruddoja, M</creator><creator>Fink, K</creator><creator>Lieberman, F</creator><creator>Phuphanich, S</creator><creator>Dunbar, E</creator><creator>Walbert, T</creator><creator>Schiff, D</creator><creator>Tran, D D</creator><creator>Ashby, L S</creator><creator>Butowski, N</creator><creator>Iwamoto, F</creator><creator>Lindsay, R</creator><creator>Bullington, J</creator><creator>Schulder, M</creator><creator>Sherman, J</creator><creator>Brooks, C</creator><creator>Reardon, D</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20181001</creationdate><title>373OResults of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)</title><author>Peereboom, D ; Nabors, L B ; Kumthekar, P ; Badruddoja, M ; Fink, K ; Lieberman, F ; Phuphanich, S ; Dunbar, E ; Walbert, T ; Schiff, D ; Tran, D D ; Ashby, L S ; Butowski, N ; Iwamoto, F ; Lindsay, R ; Bullington, J ; Schulder, M ; Sherman, J ; Brooks, C ; Reardon, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdy273_3613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peereboom, D</creatorcontrib><creatorcontrib>Nabors, L B</creatorcontrib><creatorcontrib>Kumthekar, P</creatorcontrib><creatorcontrib>Badruddoja, M</creatorcontrib><creatorcontrib>Fink, K</creatorcontrib><creatorcontrib>Lieberman, F</creatorcontrib><creatorcontrib>Phuphanich, S</creatorcontrib><creatorcontrib>Dunbar, E</creatorcontrib><creatorcontrib>Walbert, T</creatorcontrib><creatorcontrib>Schiff, D</creatorcontrib><creatorcontrib>Tran, D D</creatorcontrib><creatorcontrib>Ashby, L S</creatorcontrib><creatorcontrib>Butowski, N</creatorcontrib><creatorcontrib>Iwamoto, F</creatorcontrib><creatorcontrib>Lindsay, R</creatorcontrib><creatorcontrib>Bullington, J</creatorcontrib><creatorcontrib>Schulder, M</creatorcontrib><creatorcontrib>Sherman, J</creatorcontrib><creatorcontrib>Brooks, C</creatorcontrib><creatorcontrib>Reardon, D</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peereboom, D</au><au>Nabors, L B</au><au>Kumthekar, P</au><au>Badruddoja, M</au><au>Fink, K</au><au>Lieberman, F</au><au>Phuphanich, S</au><au>Dunbar, E</au><au>Walbert, T</au><au>Schiff, D</au><au>Tran, D D</au><au>Ashby, L S</au><au>Butowski, N</au><au>Iwamoto, F</au><au>Lindsay, R</au><au>Bullington, J</au><au>Schulder, M</au><au>Sherman, J</au><au>Brooks, C</au><au>Reardon, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>373OResults of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)</atitle><jtitle>Annals of oncology</jtitle><date>2018-10-01</date><risdate>2018</risdate><volume>29</volume><issue>suppl_8</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Oxford University Press</pub><doi>10.1093/annonc/mdy273.361</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2018-10, Vol.29 (suppl_8) |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_oup_primary_10_1093_annonc_mdy273_361 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | 373OResults of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A47%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=373OResults%20of%20phase%20II%20trial%20of%20SL-701,%20a%20novel%20immunotherapy%20targeting%20IL-13Ra2,%20EphA2,%20and%20survivin,%20in%20adults%20with%20second-line%20recurrent%20glioblastoma%20(GBM)&rft.jtitle=Annals%20of%20oncology&rft.au=Peereboom,%20D&rft.date=2018-10-01&rft.volume=29&rft.issue=suppl_8&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy273.361&rft_dat=%3Coup%3E10.1093/annonc/mdy273.361%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdy273.361&rfr_iscdi=true |